» Articles » PMID: 24282461

The Effects of Cigarette Smoking on Prostate-specific Antigen in Two Different Age Groups

Overview
Specialty Urology
Date 2013 Nov 28
PMID 24282461
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Background: We investigate the effects of cigarette smoking on prostate-specific antigen (PSA) using 2 different age groups.

Methods: The study was carried out between January 2007 and October 2011 with men; the 2 sets of age groups were: 25 to 35 years and 50 to 70 years old. The participants were divided into 4 groups. Of the 25 to 35 age range, smokers were Group 1, and non-smokers were Group 2; of the 50 to 70 age range, smokers were Group 3 and non-smokers Group 4. In addition, for the 50 to 70 age group, the International Prostate Symptom Score was completed, digital rectal examination was performed, and transabdominal prostate volume was measured. We wanted to see whether prostate-specific antigen (PSA) levels showed a difference between the 2 age groups.

Results: There were 114 patients in Group 1, 82 in Group 2, 90 in Group 3, and 102 in Group 4. The mean PSA level was 0.7 ± 0.28 ng/mL for Group 1, and 0.6 ± 0.27 ng/mL for Group 2 (p = 0.27), and there was no statistically significant difference between the 2 groups. The mean PSA was 2.5 ± 1.8 ng/mL for Group 3, and 2.1 ± 2.0 ng/mL (p = 0.59) for Group 4, and there was no statistically significant difference between the these 2 age groups.

Interpretation: Cigarette smoking effects various hormone levels. Different from previous studies, the PSA level was higher in smokers compared to nonsmokers, although it was not statistically significant. Our study is limited by the small numbers in our study groups and the lack of PSA velocity data.

Citing Articles

Relationship between Mental Disorders, Smoking or Alcoholism and Benign Prostate Disease.

Chantada-Tirado P, Chantada-Abal V, Cozar-Ortiz J, Chantada-Tirado C, Cozar-Olmo J, Esteban-Fuertes M Clin Pract. 2024; 14(1):250-264.

PMID: 38391406 PMC: 10888384. DOI: 10.3390/clinpract14010020.


Smoking: Its Impact on Urologic Health.

Mobley D, Baum N Rev Urol. 2016; 17(4):220-5.

PMID: 26839519 PMC: 4735668.

References
1.
Hickey K, Do K, Green A . Smoking and prostate cancer. Epidemiol Rev. 2001; 23(1):115-25. DOI: 10.1093/oxfordjournals.epirev.a000776. View

2.
Shiels M, Rohrmann S, Menke A, Selvin E, Crespo C, Rifai N . Association of cigarette smoking, alcohol consumption, and physical activity with sex steroid hormone levels in US men. Cancer Causes Control. 2009; 20(6):877-86. PMC: 3004151. DOI: 10.1007/s10552-009-9318-y. View

3.
Ilyin S, Belkowski S, Plata-Salaman C . Biomarker discovery and validation: technologies and integrative approaches. Trends Biotechnol. 2004; 22(8):411-6. DOI: 10.1016/j.tibtech.2004.06.005. View

4.
Pickles T, Liu M, Berthelet E, Kim-Sing C, Kwan W, Tyldesley S . The effect of smoking on outcome following external radiation for localized prostate cancer. J Urol. 2004; 171(4):1543-6. DOI: 10.1097/01.ju.0000118292.25214.a4. View

5.
Moyad M . Lifestyle/dietary supplement partial androgen suppression and/or estrogen manipulation. A novel PSA reducer and preventive/treatment option for prostate cancer?. Urol Clin North Am. 2002; 29(1):115-24, ix. DOI: 10.1016/s0094-0143(02)00037-x. View